Photodynamic therapy for bile duct carcinoma: Phase I / Phase II clinical trial.

Photodynamic therapy for bile duct carcinoma: Phase I / Phase II clinical trial. - Photodynamic therapy for bile duct carcinoma: Phase I / Phase II clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018275

Enrollment

Registered

2015-08-31

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile duct carcinoma

Interventions

Laserphyrin 100 mg for injection

Porfimer sodium was intravenously injected at a dose of 2mg/kg body weight. An eximer dye pulsed laser with a wavelength of 630m Talaporfin sodium was intravenously injected at a dose of 40 mg/m2 4-6

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cholangiocarcinoma

Exclusion criteria

Exclusion criteria: Non

Design outcomes

Primary

Measure	Time frame
Blood and urinary porphyrin density Biochemical examination of blood	—

Countries

Japan

Contacts

Public ContactAtsushi Nanashima

University of Miyazaki Faculty of Medicine Department of Surgery Division of Hepato- Biliary -Pancreatic Surgery

a_nanashima@med.miyazaki-u.ac.jp+81-985-85-2905

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026